The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Tumor mutation burden (TMB) has been validated as a predictive biomarker for immunotherapy response and survival in numerous cancer types. Limited data is available on the inherent prognostic role of TMB in early-stage tumors. OBJECTIVE: To evaluate the prognostic role of TMB in early-st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wankhede, Durgesh, Grover, Sandeep, Hofman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475237/
https://www.ncbi.nlm.nih.gov/pubmed/37667779
http://dx.doi.org/10.1177/17588359231195199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475237/
https://www.ncbi.nlm.nih.gov/pubmed/37667779
http://dx.doi.org/10.1177/17588359231195199

Ejemplares similares